Bosses at biotech firm Circassia have unveiled plans to float on the London Stock Exchange.
The firm, based at the Oxford Science Park, specialises in allergy treatments including those for cats and grass, using its ToleroMune technology.
Chief executive Steven Harris said: “This listing will be a major strategic step for Circassia.
“We believe our products can offer allergy patients an effective short course of immunotherapy with minimal side-effects and long-lasting benefits.
“We are immensely proud of our heritage and look forward to building a leading, UK-based specialty biopharmaceutical company.”
The firm is expected to float in March.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article